Augmedix EBIT

The latest EBIT for AUGX is $-24M as of June 2024. That compares with $-22M in the prior-year period — down 12.1% year over year. That is below the sector sector average of $-6.4M. Investors often review this figure alongside Augmedix's historical trend and sector peers before judging valuation or financial health.

Over the past year, AUGX's EBIT moved from $-22M to $-24M — a 12.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Augmedix's operating scale or balance-sheet position.

Against its sector companies, AUGX currently prints $-24M for EBIT, while the sector average sits near $-6.4M. That is roughly 280.2% below the sector mean. Large gaps often invite a closer look at Augmedix's growth, margins, and balance sheet.

A EBIT figure of $-24M for AUGX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-6.4M. Explore the charts below for those layers of context.

After noting AUGX's EBIT ($-24M), review year-over-year change from $-22M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.